Teligent, Inc. (TLGT) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $0.17. It has a SharesGrow Score of 37/100, indicating a weak investment profile with 1 out of 7 criteria passed.
Financials: revenue is $45M, -10.9%/yr average growth. Net profit margin is 0% (thin). Gross margin is 100% (+48.1 pp trend).
Balance sheet: total debt is $137M with negative equity of -$110M — this means total liabilities exceed total assets. This is a warning sign that may indicate accumulated losses, aggressive share buybacks, heavy debt financing, or aggressive dividend payouts. Companies like McDonald's and Starbucks also carry negative equity due to buybacks and dividends, but investors should assess whether the business generates sufficient cash flow to service its debt and sustain payouts. Current ratio is 1.92 (strong liquidity). Debt-to-assets is 163.6%. Total assets: $84M.
Analyst outlook: 1 / 4 analysts rate TLGT as buy (25%) — mixed sentiment.
SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 30/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 50/100 (Partial), Future 20/100 (Fail), Income 30/100 (Fail).
